| melanoma
Tafinlar + Mekinist vs Tecentriq
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Tafinlar vs Tecentriq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTecentriq has a higher rate of injection site reactions vs Tafinlar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tecentriq but not Tafinlar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tafinlar
Tecentriq
At A Glance
Oral
Twice daily
BRAF kinase inhibitor
IV infusion
Every 2-4 weeks
PD-L1 antagonist
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Anaplastic thyroid carcinoma
- Low grade glioma
- Solid Neoplasm
- Non-Small Cell Lung Carcinoma
- Small cell carcinoma of lung
- Liver carcinoma
- Melanoma
- Alveolar Soft Part Sarcoma
Dosing
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
Non-Small Cell Lung Carcinoma (adjuvant) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV for up to 1 year, following resection and up to 4 cycles of platinum-based chemotherapy.
Non-Small Cell Lung Carcinoma (metastatic) 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV until disease progression or unacceptable toxicity; administer prior to chemotherapy and bevacizumab when given on the same day.
Small cell carcinoma of lung 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; administer prior to chemotherapy when given on the same day.
Liver carcinoma 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with bevacizumab 15 mg/kg every 3 weeks; administer prior to bevacizumab when given on the same day.
Melanoma Following a 28-day lead-in cycle of cobimetinib and vemurafenib, administer 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV with cobimetinib 60 mg once daily (21 days on/7 days off) and vemurafenib 720 mg twice daily.
Alveolar Soft Part Sarcoma Adults: 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks IV; pediatric patients >=2 years: 15 mg/kg (up to 1200 mg) every 3 weeks IV.
Contraindications
—
—
Adverse Reactions
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
Most common (>=20%) Fatigue/asthenia, decreased appetite, nausea, cough, dyspnea (single-agent); fatigue/asthenia, nausea, alopecia, constipation, diarrhea, decreased appetite (combination regimens).
Serious Pneumonia, pneumonitis, sepsis, pyrexia, febrile neutropenia, pulmonary embolism, hepatotoxicity, gastrointestinal hemorrhage.
Postmarketing Pericarditis, pericardial effusion, cardiac tamponade, tenosynovitis.
Pharmacology
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
Atezolizumab is a PD-L1 antagonist monoclonal antibody that binds to PD-L1 and blocks its interactions with both PD-1 and B7.1 receptors, releasing PD-L1/PD-1-mediated inhibition of the immune response, including activation of the anti-tumor immune response without inducing antibody-dependent cellular cytotoxicity.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tafinlar
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Tecentriq
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Tafinlar
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
Tecentriq
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Tafinlar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Tecentriq
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tafinlar.
No savings programs available for Tecentriq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TafinlarView full Tafinlar profile
TecentriqView full Tecentriq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.